Articles from Kenvue

Kenvue Inc. (NYSEKVUE) will announce its fourth quarter and full year 2024 financial results before market open on February 6, 2025.

Kenvue Inc. (NYSEKVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue’s common stock. This quarterly dividend is payable on February 26, 2025, to shareholders of record as of the close of business on February 12, 2025.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) today announced the Company’s participation in the Morgan Stanley Global Consumer & Retail Conference in New York City. Thibaut Mongon, Chief Executive Officer and Paul Ruh, Chief Financial Officer will participate in a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. A live webcast of the fireside chat will be available on investors.kenvue.com and a replay will be available on the website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), today announced financial results for the fiscal third quarter ended September 29, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced its Neutrogena® brand is taking dermatological beauty to the next level by establishing multi-year partnerships with Dr. Dhaval Bhanusali, renowned skincare innovator, and Dr. Muneeb Shah, the most followed dermatologist worldwide2.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its third quarter 2024 financial results before market open on November 7, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on Kenvue’s common stock. This quarterly dividend is payable on November 27, 2024, to shareholders of record as of the close of business on November 13, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue” or the “Company”), the maker of iconic brands such as Aveeno®, Listerine®, Neutrogena® and Tylenol®, is advancing progress toward the climate change goals outlined in its Healthy Lives Mission environmental, social and governance strategy, including releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) today announced the Company’s participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), today announced financial results for the fiscal second quarter ended June 30, 2024.

Kenvue Inc. (“Kenvue” or the “Company”) (NYSEKVUE), the world’s largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors (“the Board”) succession process, in line with the Company’s commitment to best-in-class corporate governance and independent Board oversight.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced a 2.5% increase in the Company’s quarterly dividend as its Board of Directors declared a $0.205 per share dividend on Kenvue common stock payable in the third quarter of 2024. This is a testament to the Company’s commitment to return cash to shareholders as part of its capital allocation strategy designed to enable sustainable growth and optimize total shareholder return. The third quarter dividend is payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the second quarter ending June 30, 2024, before market open on August 6, 2024.

Kenvue Inc. (NYSEKVUE) (“Kenvue” or the “Company”), the world’s largest pure-play consumer health company by revenue, today released its first-ever Healthy Lives Mission Report and shared how the Company advanced the well-being of both people and planet in 2023.

Kenvue Inc. (NYSEKVUE) (“Kenvue”) announced today the pricing of its previously announced secondary underwritten public offering (the “Offering”) of 182,329,550 shares of its common stock (the “Shares”) at a public offering price of $20.00 per share. The Offering is expected to close on May 17, 2024, subject to the satisfaction or waiver of customary closing conditions. Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange (as described below).